Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q4G0W2
UPID:
DUS28_HUMAN
Alternative names:
-
Alternative UPACC:
Q4G0W2
Background:
Dual specificity phosphatase 28 (DUSP28) exhibits unique phosphatase activity, preferentially dephosphorylating synthetic substrates like 6,8-difluoro-4-methylumbelliferyl phosphate. Its activity profile is characterized by negligible action on phosphotyrosine and even lower on phosphothreonine, with no activity on phosphoserine. This specificity suggests a highly selective mechanism, potentially influenced by steric hindrance at the active site.
Therapeutic significance:
Understanding the role of Dual specificity phosphatase 28 could open doors to potential therapeutic strategies.